Ensysce Biosciences (NASDAQ:ENSC) stock is in the news today as retail traders take interest in the company with plenty of chatter on social media. Image of a penny held between two fingers with a ...

Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing novel opioids that provide the needed pain relief, while greatly limiting the potential for abuse and overdoses that ...

Ensysce Biosciences shares are trading lower by 30% during Thursday's session. The company announced a $5 million registered direct offering and concurrent private placement. Post-Labor Day Trading ...

Short interest in Ensysce Biosciences Inc (NASDAQ:ENSC) increased during the last reporting period, rising from 144.54K to 344.43K. This put 14.69% of the company's publicly available shares short.

Fintel reports that on September 25, 2023, HC Wainwright & Co. maintained coverage of Ensysce Biosciences (NASDAQ:ENSC) with a Buy recommendation. As of August 31, 2023, the average one-year price ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Ensysce Biosciences (NASDAQ:ENSC) stock is in the news today as retail traders take interest in the company with plenty of chatter on social media. Source: Shutterstock The extra attention on ENSC ...